First Tracks Biotherapeutics, Inc. (TRAX) stock
TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026
$43.57−2.99 (-6.42%)
Close on Nov 17, 2026Market cap $1.56BP/E –Yield –
First Tracks Biotherapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
No revenue figures for First Tracks Biotherapeutics
First Tracks Biotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?